/92-35_files/92-3500001im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
Lesson35
Basic
Neurochemistry
Objectives:
To
familiarize the students with
the
Various
NT and their role in the modulation of
behaviors
Classification
of Neurotransmitters. Monoamines:
Catechoalimnes
and
Indolemaine,
acetylcholine,
amino acid, and Peptide
Neurotransmitters
role in modulation of behaviors and
Aberration
Drugs
and Behavior:
Classification
of Psychopharmacological substances
Behavioral
correlates, Treatment:
Mechanism
of synaptic transmission
Main
purpose:
We
continue our discussion on the
control and involvement of 5HT in
behaviors
5HT
and Behaviors:
We
will now proceed to discuss
the behaviors which are
affected, modified changed or
controlled by
5HT
There
are some very important
behaviors regulated by 5HT
ranging from temperature regulation
to
sleep,
anxiety and depression
1.
Temperature regulation: temperature
regulation is an important motivational
behavior dependent on
the
day and night cycles. If
5HT is injected intraventrically it
leads to increased body
temperature.
PCPA
is injected to deplete brain
serotonin and after this
depletion, raphe nuclei are
electrically
stimulated
no rise in body temperature take place.
The body temperature would
otherwise rise with the
stimulation
of raphe nuclei (increased serotnonin,leads to
increasedbody temperature).
2.
Sensory perception: 5HT
involved in producing the heightened
sensory and
visuomotor
hallucinogenic
effect of LSD. We have talked
about LSD effects take place
through the serotonergic
system.
Injections of PCPA(which depletes
brain serotonin), reduced
motor activity, and
reduced
emotional
reactivity, but increased
sensitivity to pain (means
that in rats the electrical
current given for a
response
is much lower-they respond at a
lower current with avoidance
and other behaviors).
Further,
when
5HT levels are decreased
this slows down the process of tolerance
to morphine (tolerance means
that
the effectiveness of drug dosage is
lessened, so the dosage has to be
increased to have the same
effect
of response).
3.
Serotonin and
sleep
Evidence
for involvement of 5HT in
sleep is provided by experiments in which
levels of 5HT are
increased
by administration of MOAI (reduced deactivation) or
5HTP (increased enzymes) or
5HT. This
treatment
leads to an increase in levels of
5HT and also increase
time spent in Slow Wave
Sleep (SWS).
If
5HT is decreased then the
time spent in SWS is also
decreased.
PCPA
administration (depletes/reduces 5HT
drastically) also leads to
reduced Rapid Eye
Movement
sleep
(REM)
Jouvet
(1973) was the first one to
identify the relationship between 5HT and
sleep. Jouvet carried
out
experiments
of manipulating raphe nuclei and
seeing its effect in cats.
(Why cats are best animals
for
sleep
research as they spend
2/3rd of their life in sleep).
The electrolytic lesion of the
Raphe nuclei led to
132
/92-35_files/92-3500002im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
decreased
5HT and decreased time
spent in sleep. Sleep reduced
when 5HT was reduced
85% time in
sleep
was reduced to 20%
(insomniac cats!!)
Further
when PCPA was injected,
1-2 days after injection (
when complete depletion of brain
5HT has
taken
place) increases insomnia followed.
How was this confirmed? By
injections of 5HTP
(which
increased
5HT and reverses PCPA
induced lower levels of 5HT,
insomnia induced by PCPA
was
reversed!
4.
Other behaviours
a)
5HT
appears to be involved in Depression as there is
evidence of decreased 5HT and 5HIAA (
5HT
metabolite)
in brains of suicide victims ( Bourne et
al 1968). This indicates that in
depression 5HT is
lower
than normal levels (antidepressant
such as tricyclics and MOAI
also act to increase levels
of 5HT)
b)
Decreases
in 5 HT leads to a disinhibition of
behaviors (reduced controls on
behaviors), increased
impulsivity,
increased aggressiveness, and increased
suicidal tendencies.
c)
Serotonin
is also involved in control of sexual and
reproductive behaviors. PCPA
which depletes
5HT,
increased sex drive in
males. In females, the ovulation cycle is
blocked by narcotics; this
blockade
is
removed by administration of
5HT
Thus,
we have seen that 5HT is one
of the major neurotransmitters which
influences a wide range
of
motivational
and other behaviors.
Acetylcholine:
ACH
One
of the major neurotransmitters a class by
itself, as there is no other like
this neurotransmitter.
This
NT
has been well known
and around since 1920's.
The effects of ACH have been studied in
Bioassay
and
neuromuscular transmission (frog muscles
contraction when Ach is
applied on the muscle in the
experimental
solution) demonstrated.Ach is used by
neurons which terminate on the
neuromuscular
junction.
Since the 1960's there have been
studies suing enzymatic, gas
chromatography, flourometric
and
other studies demonstrating the
involvement of Ach in brain-behavior
modulation. This is
classified
as
an excitatory NT. Excitatory post
synaptic Potentials are
released in the muscle cell. ACH
has an
excitatory
effect on the skeletal muscles,
but it is inhibitory at heart (remember we
earlier told you
that
the
location is as important as the
classification of the NT for its actions
as excitatory or inhibitory
neurotransmitter).
ACH is also found to play an
active role in brain areas
such as hypothalamus
and
cerebral
cortex. It is involved in learning and
memory (known as the memory
molecule), and Rapid eye
Movement
sleep.
The
study of Ach is easier than
other neurotransmitters as it is easy to remove
and study outside the
brain
in petri dish. The nicotinic
receptors was the first
receptor identified (Agranoff,
p205)..
Acetylcholine
is found in ganglions of the autonomic
nervous system and the target organs
of
parasympathetic
nervous system.
This
has two distinctive types of
receptors the nicotinic- which
connects the muscle fibers and
works
through
sodium channels (these are
ionotropic receptors). Curare, a poison
can block the transmission of
Ach
at neuromuscular joints. In neuromuscular joints
nicotine mimics excitatory effects of
ACH
The
muscarinic that are found in the
CNS and these use G
proteins, cyclic AMPs as
second messengers.
These
are classified as metabotropic
receptors. Atropine blocks
these receptors, this leads
to loss of
memory
(Pinel 2002, p.
95-102)
133
/92-35_files/92-3500003im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
The
ACH receptors are known as the
cholinergic receptors
Synthesis
Acetylcholine
is synthesized in a catalytic action of
cholinesterase on the Co-enzyme A + its
acetate ion
and
Choline. It acts to detach
acetate ion from co-enzyme A and
attach it with choline to
form
acetylcholine
and separate the Co Enzyme A. The Co
Enzyme A is found in Vitamin B, and
choline is
broken
down from lipids and Acetyl
is an acetate ion. Choline is the rate
limiting factor of ach
(no
choline,
no Ach)
The
Ach is further broken down
by these enzymes Choline
acetyl transferase whereby.
Ach is broken
down
into choline and acetyl
via a process of
hydrolysis
Half
of choline in this chemical action is
retrieved and recycled
Involvement
and neuroanatomical sites of
ACH
Ach
is formed in the cell bodies of the
neuron and transported to the neuromuscular junctions.
It is
released
by action potential, crosses
over and activates the muscles
fiber.
I
a) Acetylcholine
is found at all neuromuscular junctions,
autonomic ganglion and
parasympathetic
systems
b)
Hippocampus
receives Ach input from
medial septal nucleus
c)
Ach
projects into the ascending reticular
arousal system
d)
Involved
in Auditory and Visual
systems
e)
Found
in the Caudate nucleus
f)
Found
in Ventral basal
hypothalamus
g)
In
Suproptic nucleus brain
stem
h)
Ach
acts as a sensory transmitter in
thermal receptor. Pain is produced by
directly putting Ach on to
a
blister
on the skin.
II
Ach
is involved in the:
a)
Release
of catecholamines (works to balance
other NT's and has
interaction with DA, NE,
and 5HT
in
all functions)
b)
Conduction
of signals: it acts in the axonal
conduction by depolarizing the
axon.
Steps
in ACH synthesis where drugs
can modulate action
Drugs
affecting cholinergic
synapses
Step
1. Synthesis:
Ach Synthesis can be blocked by
styryl
pyridine- a
derivative
Step
2.
Release of Ach from the
presynaptic membrane is enhanced by
B-bungarotoxin and black
widow
spider venom and blocked by butolinus
toxin-deadly food poison.
The latter acts to block
Ach
transmission
leading to total
paralysis
Step
3.
Post receptor sites can be
activated or blocked in both
type of receptors
These
are activated by Ach
agonists or cholinometic drugs and anticholinesterases
(blocking the enzyme
which
breaks down Ach)
a)
Nicotinic
receptors are blocked by
A-
Bungarotoxin and
Curare
(Tubocurarine).
Local anesthetics
and
drugs such as phencyclidine bind to
these receptors to modulate
action.
Curare,
a poison used by South
American Indians in arrows prevents Ach
from reaching post
receptor
area
(occupies the sites), since the muscles
do not get activated, this
lead to blockade of all
muscular
134
/92-35_files/92-3500004im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
responses.
Since there is no post synaptic response,
no nerve command is processed.
This leads to total
paralysis
of muscles. Poison from cobra, Alpha
bungarotoxin acts through
this mechanism
b)
Muscarinic
receptors are blocked by
atropine (belladona), and
scopolamine
Step
4. Presynaptic
receptor blockade: Atropine and scopolamine
block these
Step
5.
Inhibition of inactivation activity
leads to increase in ACH in the brain by
physostigmine
which
blocks
the acteylcholinesterase
breaking
down of Ach. This leads to
increased levels of Ach in
the
system,
resulting in repeated stimulation of
muscles. This means that the
muscles would be
repeatedly
stimulated.
This results in violent muscular
contractions.
It
is reported by (Brown and Wallace, p
40) that there is a West
Indian tribal custom where Calabar
bean
extract
is used to find if a person is
guilty or innocent. If guilty, then the
person who had taken the
bean
extract
as a test would die, and if
they were innocent the person
would swallow and
vomit.
Physostigmine
is used as a therapy for
Myasthenia
Gravis: (neurological
disorder where the
muscles
are
extremely weak, and don't
have normal levels of ACH-
for muscles to act). The drugs
given
increase
ACH (cholinometics, or anticholinesterases). Increases
in Ach using this therapy
can lead to
nightmares,
confusion and hallucination.
Receptor
Agonists: a) muscarinic
receptors are affected by muscarinic
agonists. One of them is the
muscarinic
extract from poison
mushrooms, which if taken
increases ACH activity leads to
increased
sweating,
increased salivation, constriction of
pupils and decreased heart rate. Also
muscarine, which
mimics
the inhibitory effects of ACH (Agranoff
1989), b) Nicotinic receptor agonists, in
neuromuscular
joints,
nicotine mimics the excitatory effects of
ACH
Nicotinic
agonists could be useful in the treatment
of a variety of neurological disorders
including
Alzheimer's
disease, Parkinson's disease and
chronic pain.
Receptor
Antagonists:
a)
For
Muscarinic receptors: Atropine is an antagonist for muscarinic receptors.
Atropine
Belladonna-
night
shade poison- blocks muscarinic receptors, acts as a false transmitter. It
occupies the post receptor
sites
and does not transmit message forward it cannot, it is a false molecule).
Atropine belladonna liquid
leads
to dilation of pupils when applied directly on to the eyes. Why Belladonna
(beautiful woman)
because
women used to apply it to their eyelids for wider eye look. From Grecian times,
Hippocretes
used
it for stomach ailments and cosmetics. In 1880's, the breakdown of atropine from
the belladonna
plant
affects the muscarinic receptor
Atropine
and
Scopolamine
lead
to decreased ACH in the brain leading to amnesia (reduced ACH
in
Alzheimer
brain related to their memory loss). This also indicates that ACH is involved in
learning and
memory.
Muscarinic
antagonists are used to control and prevent vomiting, are also useful for the
treatment of
Parkinson's
disease. In large doses however, the muscarinic antagonists cause severe side
effects such as
hallucinations
and memory disturbances.
Step
6. Choline
uptake. B-Bungarotoxin
and
black
spider widow
venom
Check
table 1 taken from the website, it
provides a very good summary
of the agonists and antagonist
we
have referred to above
135
/92-35_files/92-3500005im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
Table1:
Natural Cholinergic Agonist and
Antagonists
Agonists
Source
of Compound
Mode
of Action
Activates
nicotinic class
Alkaloid
prevalent in the
Nicotine
of
ACh receptors, locks
tobacco
plant
the
channel open
Alkaloid
produced by
Activates
muscarinic
Muscarine
Amanita
muscaria
class
of ACh receptors
mushrooms
Induces
massive ACh
Protein
produced by the
release,
possibly
by
a-Latrotoxin
Ca2+
black
widow spider
acting
as
a
ionophore
Antagonists
Atropine
(and related
Alkaloid
produced by the
Blocks
ACh actions only
compound
deadly
nightshade,
at
muscarinic receptors
Scopolamine)
Atropa
belladonna
Eight
proteins produced
Inhibits
the release of
Botulinus
Toxin
by
Clostridium
ACh
botulinum
Protein
produced
by
Prevents
ACh receptor
a-Bungarotoxin
Bungarus
genus
of
channel
opening
snakes
Prevents
ACh receptor
Active
ingredient
of
d-Tubocurarine
channel
opening at motor
curare
end-plate
Source:
http://web.indstate.edu/thcme/mwking/nerves.html#ach
References:
1.
Kalat J.W (1998) Biological
Psychology Brooks/ Cole
Publishing
2.
Carlson N.R. (2005) Foundations of
Physiological Psychology Allyn and Bacon,
Boston
3.
Pinel, John P.J. (2003)
Biopsychology (5th edition) Allyn and Bacon
Singapore
4
Bloom F, Nelson and Lazerson (2001),
Behavioral Neuroscience: Brain, Mind and
Behaviors (3rd
edition)
Worth Publishers New
York
5.
Bridgeman, B (1988) The
Biology of Behavior and Mind. John
Wiley and Sons New
York
6.
Brown,T.S. and Wallace.(1980) P.M
Physiological Psychology
136
/92-35_files/92-3500006im.jpg" width="718"
height="1067" useMap="#Map">
Neurological
Basis of Behavior (PSY -
610)
VU
Academic
Press New York
7.
Seigel, G.J. (Ed. in chief)
Agranoff, B.W, Albers W.R.
and Molinoff, P.B. (Eds) (1989)
Basic
Neurochemistry:
Molecular, Cellular and Medical
Aspects
8.
Cooper,J.R, F.E Bloom,and
R.H Roth (1996) Biochemical
basis of neuropharmacology 7th
Edition,
OUP
9.
Pharmacology, Biochemistry and
behavior
(Additional
references for the module: Iversen and Iversen, Gazzaniga, Bloom, and
handouts)
Note:
References
3, 8, 9 more closely followed in addition
to the references cited in
text.
137